MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the results of the matters voted upon at its Fiscal 2023 Annual Meeting of Shareholders (“AGM”) held March 6, 2024.
Shareholders voted in favour of all items of business and each item of business was approved by the requisite number of votes. The matters included the election of the Board of Directors and the appointment of auditors. The total number of shares represented, either in person or by proxy, totaled 10,665,029 or 43.232%. The voting results are detailed below.
1) The Election of the Board of Directors
Name of Nominee |
Votes FOR |
% |
Votes WITHHELD |
% |
Brent Ashton |
10,481,118 |
99.811 |
19,800 |
0.189 |
Amir Boloor |
10,405,326 |
99.090 |
95,592 |
0.910 |
Joseph Cordiano |
10,363,626 |
98.693 |
137,292 |
1.307 |
Martin Goldfarb |
10,350,326 |
98.566 |
150,592 |
1.434 |
Samantha Nutt |
10,435,784 |
99.380 |
65,134 |
0.620 |
Abe Schwartz |
10,182,126 |
96.964 |
318,792 |
3.036 |
Ron Smith |
10,373,626 |
98.788 |
127,292 |
1.212 |
2) The Appointment of the Auditor
|
Votes FOR |
% |
Votes WITHHELD |
% |
PricewaterhouseCoopers, LLP |
10,661,208 |
99.983 |
1,800 |
0.017 |
Final voting results of all matters voted on at the meeting will be filed on SEDAR+ at http://www.sedarplus.ca/ and further details of the voted matters can be found in the Company’s management information circular January 30, 2024.
A recording of the AGM and a copy of management’s presentation are available on Covalon’s website at https://ir.covalon.com/events-and-presentations/events/event-details/2024/Annual-Meeting-of-Shareholders-2024-IEG2Kp8KHg.
Those interested in learning more about Covalon’s solutions may visit www.covalon.com or follow Covalon on LinkedIn, Facebook, or Instagram.
About Covalon
Covalon is a patient-driven medical device company, that provides innovative and cost-effective healthcare solutions that aim to help reduce pain, prevent infection, and promote healing. Through a strong portfolio of patented technologies and solutions for advanced wound care, infection control, and medical device coatings, we offer innovative, gentle and more compassionate options to aid patients on their healing journey. Our solutions are designed for patients and made for care providers. Covalon leverages its patented medical technology platforms and expertise in two ways: (i) by developing products that are sold under Covalon’s name; and (ii) by developing and commercializing medical products for other medical companies under development and license contracts. The Company is listed on the TSX Venture Exchange, having the symbol COV and trades on the OTCQX Market under the symbol CVALF. To learn more about Covalon, visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur”, or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management’s expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the “Risks and Uncertainties” section of our management’s discussion and analysis of financial condition and results of operations for the year ended September 30, 2023, which is available on the Company’s profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
